These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34859741)

  • 1. Hyaluronic acid-coated and Olaparib-loaded PEI - PLGA nanoparticles for the targeted therapy of triple negative breast cancer.
    Hu H; Zhang Y; Ji W; Mei H; Wu T; He Z; Wang K; Shi C
    J Microencapsul; 2022 Jan; 39(1):25-36. PubMed ID: 34859741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-delivery of gambogic acid and TRAIL plasmid by hyaluronic acid grafted PEI-PLGA nanoparticles for the treatment of triple negative breast cancer.
    Wang S; Shao M; Zhong Z; Wang A; Cao J; Lu Y; Wang Y; Zhang J
    Drug Deliv; 2017 Nov; 24(1):1791-1800. PubMed ID: 29172759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy.
    Wang S; Zhang J; Wang Y; Chen M
    Nanomedicine; 2016 Feb; 12(2):411-20. PubMed ID: 26711968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer.
    Basu A; Upadhyay P; Ghosh A; Bose A; Gupta P; Chattopadhyay S; Chattopadhyay D; Adhikary A
    Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129841. PubMed ID: 33412224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyaluronic acid-coated pH sensitive poly (β-amino ester) nanoparticles for co-delivery of embelin and TRAIL plasmid for triple negative breast cancer treatment.
    Xu Y; Liu D; Hu J; Ding P; Chen M
    Int J Pharm; 2020 Jan; 573():118637. PubMed ID: 31550511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olaparib@human serum albumin nanoparticles as sustained drug-releasing tumour-targeting nanomedicine to inhibit growth and metastasis in the mouse model of triple-negative breast cancer.
    Vysyaraju NR; Paul M; Ch S; Ghosh B; Biswas S
    J Drug Target; 2022 Dec; 30(10):1088-1105. PubMed ID: 35723068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of biodegradable PLGA nanoparticles surface engineered with hyaluronic acid for targeted delivery of paclitaxel to triple negative breast cancer cells.
    Cerqueira BBS; Lasham A; Shelling AN; Al-Kassas R
    Mater Sci Eng C Mater Biol Appl; 2017 Jul; 76():593-600. PubMed ID: 28482569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyaluronic acid-decorated PLGA-PEG nanoparticles for targeted delivery of SN-38 to ovarian cancer.
    Vangara KK; Liu JL; Palakurthi S
    Anticancer Res; 2013 Jun; 33(6):2425-34. PubMed ID: 23749891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Facile fabrication of robust, hyaluronic acid-surfaced and disulfide-crosslinked PLGA nanoparticles for tumor-targeted and reduction-triggered release of docetaxel.
    Wang X; Cheng R; Zhong Z
    Acta Biomater; 2021 Apr; 125():280-289. PubMed ID: 33677162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel redox/pH dual-responsive and hyaluronic acid-decorated multifunctional magnetic complex micelle for targeted gambogic acid delivery for the treatment of triple negative breast cancer.
    Sang MM; Liu FL; Wang Y; Luo RJ; Huan XX; Han LF; Zhang ZT; Feng F; Qu W; Liu W; Zheng F
    Drug Deliv; 2018 Nov; 25(1):1846-1857. PubMed ID: 30334478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodegradable nanoparticles sequentially decorated with Polyethyleneimine and Hyaluronan for the targeted delivery of docetaxel to airway cancer cells.
    Maiolino S; Russo A; Pagliara V; Conte C; Ungaro F; Russo G; Quaglia F
    J Nanobiotechnology; 2015 Apr; 13():29. PubMed ID: 25888948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Designing and Formulation Optimization of Hyaluronic Acid Conjugated PLGA Nanoparticles of Tamoxifen for Tumor Targeting.
    Paswan SK; Saini TR; Jahan S; Ganesh N
    Pharm Nanotechnol; 2021; 9(3):217-235. PubMed ID: 33745427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multifunctional magnetic nanosystem based on "two strikes" effect for synergistic anticancer therapy in triple-negative breast cancer.
    Zhang Y; Hu H; Tang W; Zhang Q; Li M; Jin H; Huang Z; Cui Z; Xu J; Wang K; Shi C
    J Control Release; 2020 Jun; 322():401-415. PubMed ID: 32246976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyaluronic acid coating on the surface of curcumin-loaded ZIF-8 nanoparticles for improved breast cancer therapy: An in vitro and in vivo study.
    Yu S; Wang S; Xie Z; Yu S; Li L; Xiao H; Song Y
    Colloids Surf B Biointerfaces; 2021 Jul; 203():111759. PubMed ID: 33892283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer Analysis of CD44 Targeted Cyclosporine Loaded Thiolated Chitosan Nanoformulations for Sustained Release in Triple-Negative Breast Cancer.
    Abduh MS
    Int J Nanomedicine; 2023; 18():5713-5732. PubMed ID: 37849642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted and controlled drug delivery system loading artersunate for effective chemotherapy on CD44 overexpressing cancer cells.
    Tran TH; Nguyen TD; Van Nguyen H; Nguyen HT; Kim JO; Yong CS; Nguyen CN
    Arch Pharm Res; 2016 May; 39(5):687-94. PubMed ID: 27015824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. pH-Responsive Hyaluronic Acid Nanoparticles for Enhanced Triple Negative Breast Cancer Therapy.
    Zeng X; Wang H; Zhang Y; Xu X; Yuan X; Li J
    Int J Nanomedicine; 2022; 17():1437-1457. PubMed ID: 35369031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitochondria Targeting and Destabilizing Hyaluronic Acid Derivative-Based Nanoparticles for the Delivery of Lapatinib to Triple-Negative Breast Cancer.
    Lee SY; Cho HJ
    Biomacromolecules; 2019 Feb; 20(2):835-845. PubMed ID: 30566834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted delivery of curcumin in breast cancer cells via hyaluronic acid modified mesoporous silica nanoparticle to enhance anticancer efficiency.
    Ghosh S; Dutta S; Sarkar A; Kundu M; Sil PC
    Colloids Surf B Biointerfaces; 2021 Jan; 197():111404. PubMed ID: 33142257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and characterization of hyaluronic acid modified PLGA based nanoparticles for improved efficacy of cisplatin in solid tumor.
    Alam N; Koul M; Mintoo MJ; Khare V; Gupta R; Rawat N; Sharma PR; Singh SK; Mondhe DM; Gupta PN
    Biomed Pharmacother; 2017 Nov; 95():856-864. PubMed ID: 28903181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.